ArticleNature2023
MEN1 mutations mediate clinical resistance to menin inhibition.
Open access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers.
0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed
34.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 226 citations in OpenAlex.
- A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.Journal of hematology & oncology · 2025Trial
- Article
- Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.British journal of cancer · 2026Review
- MEN1/menin deficiency suppresses hepatocellular carcinogenesis via disrupting mitophagy-mediated mitochondrial homeostasis.Autophagy · 2026Article
- Two Decades ofCancers · 2026Review
- Promiscuous RNA binding by WDR5 remodels the KMT2A (MLL1) histone methyltransferase complex to an inactive state.Molecular cell · 2026Article
- The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy.Leukemia · 2026Article
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy.Cancers · 2026Review
- Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models.Blood · 2026Article
- Menin inhibitors as a treatment for acute leukemia: from bench to the clinic.Blood neoplasia · 2026Review
- Article
- Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL-Fusion Leukemia.Cancer science · 2026Article
- Therapeutic Advances in Adult B-cell Acute Lymphoblastic Leukemia with KMT2A Rearrangements.Annals of hematology · 2026Review
- Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.Blood advances · 2026Article
- Epigenetic Regulation in Acute Myeloid Leukemia: Molecular Mechanisms and Clinical Implications.Cancers · 2026Review
- Combined inhibition of DOT1L and BCL-2 induces synergistic anti-leukemic effects in MLL-rearranged acute myeloid leukemia via suppression of the PI3K/AKT pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- An integrated analysis of MEN1 reveals its associations with clinical outcomes, cellular pathways, and the immune microenvironment.World journal of surgical oncology · 2026Article
- Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors.Blood cancer journal · 2026Article
- Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 7 institutions in 2 countries.
Florian Perner *Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Eytan M Stein *Leukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniela V WengeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0064-9104
Sukrit SinghComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeonghyeon KimDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Athina ApazidisDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Homa RahnamounDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0555-2328
Disha AnandDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Christian MarinaccioDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Charlie HattonDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Yanhe WenDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7526-2633
David SchallerIn silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Shoron MowlaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenbin XiaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8586-8500
Holly A GamlenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3746-2909
Aaron J StonestromLeukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0602-1158
Sonali PersaudHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elizabeth EnerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4147-1146
Jevon A CutlerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
John G DoenchGenetic Perturbation Platform, Broad Institute, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3707-9889
Gerard M McGeehanSyndax Pharmaceuticals, Waltham, MA, USA.
Andrea VolkamerIn silico Toxicology and Structural Bioinformatics, Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
John D ChoderaComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-0542-119X
Radosław P NowakDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7337-6306
Ross L LevineLeukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leviner@mskcc.org.ORCID http://orcid.org/0000-0002-7884-1905
Scott A ArmstrongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. scott_armstrong@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-9099-4728
Sheng F CaiLeukemia Service, Department of Medicine, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. cais1@mskcc.org.ORCID http://orcid.org/0000-0002-2708-887X
Boston Children's Hospital · USMemorial Sloan Kettering Cancer Center · USHarvard University · USCharité - Universitätsmedizin Berlin · DEBroad Institute · USDana-Farber Cancer Institute · USSynta Pharmaceuticals (United States) · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5MSynergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI GRAUBERT, TIMOTHY A · 2017 to 2021
$10.6MRole of TET2 mutations in malignant transformation and acute myeloid leukemiaR01CA173636 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2013 to 2022
$6.3MTargeting to Epigenetic Modications in ALLR01CA176745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ARMSTRONG, SCOTT A, QI, JUN · 2012 to 2022
$4.2MThe molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.R01CA214608 · NCI · DANA-FARBER CANCER INST · PI Eric Sebastian Fischer · 2017 to 2026
$4.0MFunctional and Mechanistic Study of Histone Crotonylation in Hematological MalignanciesR01CA204639 · NCI · ROCKEFELLER UNIVERSITY · PI ALLIS, CHARLES DAVID, ARMSTRONG, SCOTT A · 2016 to 2020
$3.5MThe role of reorganization energy in achieving selective kinase inhibition"R01GM121505 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI CHODERA, JOHN DAMON · 2017 to 2021
$1.8MAssessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemiaK08CA267058 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI XIAO, WENBIN · 2022 to 2025
$1.1MInvestigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapiesK08CA241371 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAI, SHENG · 2021 to 2024
$1.0MDefining IKZF1/IKAROS as an oncogene and therapeutic target in MLL-r AMLF32CA250240 · NCI · DANA-FARBER CANCER INST · PI CUTLER, JEVON · 2020 to 2022
$204kNCI NIH HHS CA066966NCI NIH HHS F32 CA250240NCI NIH HHS F32CA250240-02NCI NIH HHS K08 CA241371NCI NIH HHS K08 CA267058NCI NIH HHS P01 CA066996NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA173636NCI NIH HHS R01 CA176745NCI NIH HHS R01 CA204639NCI NIH HHS R01 CA214608NCI NIH HHS R35 CA197594NIGMS NIH HHS R01 GM121505
Abstract
Chromatin-binding proteins are critical regulators of cell state in haematopoiesis
Indexed as
Drug Resistance, NeoplasmLeukemiaMutationProto-Oncogene ProteinsAnimalsAntineoplastic AgentsBinding SitesChromatinHistone-Lysine N-MethyltransferaseHumansMyeloid-Lymphoid Leukemia ProteinNucleophosminProtein BindingAntineoplastic AgentsChromatinHistone-Lysine N-MethyltransferaseKMT2A protein, humanMEN1 protein, humanMyeloid-Lymphoid Leukemia ProteinNPM1 protein, humanNucleophosminProto-Oncogene Proteins
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.